{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:21:13Z","timestamp":1794932473662,"version":"4.9.1"},"reference-count":64,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Psoriasis is a chronic immune-mediated skin disease with an estimated global prevalence of 3%. Real-world studies have demonstrated that biologic therapies have transformed the management of moderate-to-severe psoriasis by providing optimal disease control and a favorable safety profile. However, a new challenge lies in identifying those most likely to achieve an early and sustained response, defined as \u2018super-responders\u2019 (SRs). This is particularly relevant given recent evidence suggesting that IL-23 inhibitors may have long-term disease-modifying effects by acting on tissue-resident memory T cells. Identifying positive and negative baseline predictors associated with achieving SR status in patients treated with anti-IL-23 agents. Methods: This retrospective observational study analyzed data from the electronic medical records of IRCCS Humanitas Research Hospital between June 2021 and June 2025. A total of 611 patients with moderate-to-severe psoriasis who were treated with risankizumab, guselkumab or tildrakizumab were included in the study. Clinical assessments were conducted at baseline and weeks 16, 28 and 52. SR status was defined as achieving a PASI score of \u22641 at week 16, with this score being maintained through weeks 28 and 52. Results: Of the 611 enrolled patients, 390 (63.8 %) achieved SR status. In multivariate logistic regression, disease duration \u2264 2 years was the strongest independent predictor (Odds Ratio [OR] 2.47, p = 0.025), followed by bio-na\u00efve status (OR 1.53, p = 0.019). Obesity (OR 0.71, 95 % CI 0.45\u20131.13) and cardiometabolic comorbidities (OR 0.93, 95 % CI 0.63\u20131.38) were not significantly associated with response after adjustments. No serious adverse events or treatment discontinuations occurred during 52 weeks of follow-up. Conclusions: Shorter disease duration (\u22642 years) and bio-na\u00efve status were identified as independent predictors of SR status. Identifying these patients could inform the development of personalized treatment strategies, including dose optimization and extended dosing intervals.<\/jats:p>","DOI":"10.3390\/jcm14186371","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T08:43:54Z","timestamp":1757493834000},"page":"6371","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Predictors of Super-Responder Status to Anti-IL-23 Therapies in Moderate-to-Severe Plaque Psoriasis: A Real-World Monocenter Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3780-5318","authenticated-orcid":false,"given":"Sara","family":"Di Giulio","sequence":"first","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Falcidia","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0527-706X","authenticated-orcid":false,"given":"Giulio","family":"Foggi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9859-4475","authenticated-orcid":false,"given":"Matteo","family":"Bianco","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1676","authenticated-orcid":false,"given":"Luigi","family":"Gargiulo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7876-4866","authenticated-orcid":false,"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1086\/503821","article-title":"Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene","volume":"78","author":"Nair","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12016-024-08991-7","article-title":"The Immunology of Psoriasis-Current Concepts in Pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","article-title":"Current severe psoriasis and the rule of tens","volume":"152","author":"Finlay","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1007\/s13555-023-01024-9","article-title":"Topical Treatment for the Management of Mild-to-Moderate Psoriasis: A Critical Appraisal of the Current Literature","volume":"13","author":"Fargnoli","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jdv.16926","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 2: Specific clinical and comorbid situations","volume":"35","author":"Nast","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","first-page":"1","article-title":"Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis","volume":"157","author":"Gisondi","year":"2022","journal-title":"Ital. J. Dermatol. Venerol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: A randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s13555-023-01075-y","article-title":"Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)","volume":"14","author":"Gooderham","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2393376","DOI":"10.1080\/09546634.2024.2393376","article-title":"Efficacy and safety of bimekizumab in elderly patients: Real-world multicenter retrospective study\u2014IL PSO (Italian Landscape Psoriasis)","volume":"35","author":"Orsini","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Cheng, Y., Ma, J., and Niu, J. (2025). Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS). PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0323973"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kruczek, W., Fr\u0105tczak, A., Litwi\u0144ska-Inglot, I., Polak, K., Pawlus, Z., Rutecka, P., Bergler-Czop, B., and Mizio\u0142ek, B. (2025). Comparative Analysis of the Long-Term Real-World Efficacy of Interleukin-17 Inhibitors in a Cohort of Patients with Moderate-to-Severe Psoriasis Treated in Poland. J. Clin. Med., 14.","DOI":"10.3390\/jcm14155421"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Orsini, D., Graceffa, D., Burlando, M., Campanati, A., Campione, E., Guarneri, C., Narcisi, A., Pella, P., Romita, P., and Travaglini, M. (2025). Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients\u2014IL PSO (Italian Landscape Psoriasis). J. Clin. Med., 14.","DOI":"10.3390\/jcm14041087"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2350760","DOI":"10.1080\/09546634.2024.2350760","article-title":"Comparative effectiveness of tildrakizumab 200\u2009mg versus tildrakizumab 100\u2009mg in psoriatic patients with high disease burden or above 90\u2009kg of body weight: A 16-week multicenter retrospective study\u2014IL PSO (Italian landscape psoriasis)","volume":"35","author":"Gargiulo","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s13555-025-01416-z","article-title":"Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis)","volume":"15","author":"Valenti","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","article-title":"Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study","volume":"23","author":"Torres","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Gargiulo, L., Ibba, L., Malagoli, P., Amoruso, F., Argenziano, G., Balato, A., Bardazzi, F., Burlando, M., Carrera, C.G., and Damiani, G. (2024). Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS). J. Clin. Med., 13.","DOI":"10.3390\/jcm13020495"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","article-title":"Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: Results from an Italian 28-week retrospective study","volume":"33","author":"Megna","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1007\/s13555-025-01476-1","article-title":"Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA-IL PSO (Italian Landscape Psoriasis)","volume":"15","author":"Valenti","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Krueger, J.G., Eyerich, K., Kuchroo, V.K., Ritchlin, C.T., Abreu, M.T., Elloso, M.M., Fourie, A., Fakharzadeh, S., Sherlock, J.P., and Yang, Y.-W. (2024). IL-23 past, present, and future: A roadmap to advancing IL-23 science and therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1331217"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): Results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e049822","DOI":"10.1136\/bmjopen-2021-049822","article-title":"IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: Rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)","volume":"11","author":"Eyerich","year":"2021","journal-title":"BMJ Open"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1111\/jdv.19599","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study: An analysis with considerations for future studies","volume":"38","author":"Javaid","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/bjd.20963","article-title":"The biological basis of disease recurrence in psoriasis: A historical perspective and current models","volume":"186","author":"Puig","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"eabq3254","DOI":"10.1126\/sciimmunol.abq3254","article-title":"Local IL-23 is required for proliferation and retention of skin-resident memory TH17 cells","volume":"7","author":"Whitley","year":"2022","journal-title":"Sci. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/ijd.15784","article-title":"Super responders to guselkumab treatment in moderate-to-severe psoriasis: A real clinical practice pilot series","volume":"61","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s13555-025-01394-2","article-title":"Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study","volume":"15","author":"Mortato","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1111\/jdv.19464","article-title":"A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS)","volume":"38","author":"Gargiulo","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_45","unstructured":"European Medicines Agency (2025, June 26). Skyrizi (Risankizumab): Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/skyrizi."},{"key":"ref_46","unstructured":"European Medicines Agency (2025, June 26). Tremfya (Guselkumab): Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tremfya."},{"key":"ref_47","unstructured":"European Medicines Agency (2025, June 26). Ilumetri (Tildrakizumab): Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ilumetri."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2199108","DOI":"10.1080\/09546634.2023.2199108","article-title":"Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: A real-life retrospective study","volume":"34","author":"Ibba","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/bjd\/ljad280","article-title":"How to define a \u2018super-responder\u2019 to biologics in psoriasis studies","volume":"189","author":"Thomas","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/jdv.18474","article-title":"Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: Age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator\u2019s Global Assessment scores predict complete skin clearance","volume":"36","author":"Reich","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2331782","DOI":"10.1080\/09546634.2024.2331782","article-title":"Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: A real-life cohort study on the effectiveness and drug survival over one-year","volume":"35","author":"Liu","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1080\/09546634.2021.1898528","article-title":"Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis","volume":"33","author":"Feldman","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/jdv.18825","article-title":"Brodalumab in plaque psoriasis: Real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104\u2009weeks","volume":"37","author":"Rompoti","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/exd.14731","article-title":"\u201cSuperresponders\u201d at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors","volume":"32","author":"Mastorino","year":"2023","journal-title":"Exp. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40257-025-00949-5","article-title":"Disease Modification in Psoriasis: Future Prospects for Long-Term Remission","volume":"26","author":"Ranzinger","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Reich","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","article-title":"Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial","volume":"160","author":"Eyerich","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/jdv.18126","article-title":"Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: A nationwide study","volume":"36","author":"Loft","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Marcelli, L., Belcastro, A., Talamonti, M., Paganini, C., Fico, A., Savastano, L., Di Raimondo, C., Vellucci, L., Bianchi, L., and Galluzzo, M. (2024). Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience. J. Clin. Med., 13.","DOI":"10.3390\/jcm13175175"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1111\/jdv.15659","article-title":"High-resolution HLA typing identifies a new \u2018super responder\u2019 subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02\/HLA-C*04, in response to ustekinumab","volume":"33","author":"Talamonti","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2425029","DOI":"10.1080\/09546634.2024.2425029","article-title":"Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: A single-center retrospective study","volume":"35","author":"Ibba","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2220849","DOI":"10.1080\/09546634.2023.2220849","article-title":"Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: A real-world experience from two referral centers","volume":"34","author":"Orsini","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Shi, W., Zhao, Z., Zhai, Y., Ye, X., and Xu, F. (2025). Adverse events associated with IL-23 and IL-12\/23 inhibitors in the clinical management of psoriasis: A comprehensive pharmacovigilance analysis. BMC Pharmacol. Toxicol., 26.","DOI":"10.1186\/s40360-025-00837-y"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2241585","DOI":"10.1080\/09546634.2023.2241585","article-title":"Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: A monocentric retrospective study","volume":"34","author":"Ibba","year":"2023","journal-title":"J. Dermatol. Treat."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/18\/6371\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:43:00Z","timestamp":1760035380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/18\/6371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":64,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["jcm14186371"],"URL":"https:\/\/doi.org\/10.3390\/jcm14186371","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}